Compulsory licensing threat in Europe requires vigilance from pharma patent owners
Reset password
Register to access two of our subscriber only articles per month.
Register
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe
Author | Life sciences reporter
[email protected]
@IAM_magazine This week's IAM Sunday Supplement is now out, including: Apple hit with $1.4bn suit; Bristol Myers IP head exclusiv… https://t.co/RWGUl8rlV2 Read more
@IAM_magazine China will play a huge role in shaping the future of video compression technology - and the way the IP surrounding… https://t.co/uCbU0we9aC Read more
@IAM_magazine Who will grant first? “Defendants’ position is anti-intellectual property and anti-business, and it puts American b… https://t.co/CTDQnid2hc Read more
@IAM_magazine RPX picks up patent portfolio from failed AR biz as defensive player makes largest acquisition in years… https://t.co/qvh9Mz49HI Read more
